Gamco Investors INC. ET AL increased its position in shares of Bausch Health Companies Inc. (NYSE:BHC – Free Report) by 4.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,440,945 shares of the company’s stock after purchasing an additional 63,700 shares during the period. Gamco Investors INC. ET AL owned 0.40% of Bausch Health Companies worth $11,528,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Public Sector Pension Investment Board increased its holdings in Bausch Health Companies by 7.3% in the first quarter. Public Sector Pension Investment Board now owns 602,663 shares of the company’s stock valued at $4,876,000 after buying an additional 41,211 shares in the last quarter. Mackenzie Financial Corp increased its position in shares of Bausch Health Companies by 4.2% in the 2nd quarter. Mackenzie Financial Corp now owns 1,138,717 shares of the company’s stock worth $9,110,000 after purchasing an additional 45,768 shares during the last quarter. BNP Paribas Arbitrage SNC increased its position in shares of Bausch Health Companies by 17,200.6% in the 1st quarter. BNP Paribas Arbitrage SNC now owns 3,016,183 shares of the company’s stock worth $24,431,000 after purchasing an additional 2,998,749 shares during the last quarter. Barclays PLC boosted its holdings in shares of Bausch Health Companies by 198.5% in the 2nd quarter. Barclays PLC now owns 954,226 shares of the company’s stock valued at $7,633,000 after buying an additional 634,551 shares during the period. Finally, Mach 1 Financial Group LLC acquired a new position in Bausch Health Companies during the 1st quarter valued at about $15,148,000. Institutional investors and hedge funds own 74.56% of the company’s stock.
Bausch Health Companies Stock Up 2.1 %
Shares of NYSE BHC opened at $7.05 on Tuesday. The firm has a market capitalization of $2.54 billion, a PE ratio of -2.67 and a beta of 0.98. The firm’s 50-day moving average is $7.56 and its 200-day moving average is $7.91. The company has a current ratio of 1.20, a quick ratio of 0.89 and a debt-to-equity ratio of 74.20. Bausch Health Companies Inc. has a 1 year low of $5.57 and a 1 year high of $10.23.
Insiders Place Their Bets
Analyst Upgrades and Downgrades
A number of analysts recently commented on the stock. StockNews.com downgraded shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. Royal Bank of Canada upped their price objective on shares of Bausch Health Companies from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Monday, July 24th. Finally, Jefferies Financial Group raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating and upped their price objective for the stock from $9.00 to $16.00 in a report on Wednesday, September 20th.
Bausch Health Companies Company Profile
Bausch Health Companies Inc operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
- Five stocks we like better than Bausch Health Companies
- How to Invest in Electric Cars
- Safeguard your portfolio with these three bargain stocks
- How to Invest in Mining Stocks
- Membership clubs gain leverage for the consumer rebound
- 3 Healthcare Dividend Stocks to Buy
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.